What caused the volume spike in 2496.HK stock today?

No public earnings or filings explain the spike; the surge to **39,400.00** shares likely reflects concentrated buy orders, trade positioning, or sector chatter. Traders should monitor company releases and regulatory filings for confirmation.

What is Meyka AI's short-term forecast for 2496.HK stock?

Meyka AI's forecast model projects a quarterly target of **HKD 9.05**, about **15.00%** above the current **HKD 7.87**. These are model projections and not guarantees.

How should intraday traders approach 2496.HK stock after the volume spike?

Treat the move as momentum-driven: set partial profit at **HKD 8.35**, trail stops below **HKD 7.80**, and size positions for high volatility. Overbought indicators raise pullback risk.

Does Wuhan YZY Biopharma have strong fundamentals for a long-term buy?

Fundamentals are mixed: negative EPS **-HKD 0.45** and PE **-17.49** contrast with cash per share **HKD 0.86** and heavy R&D spend. We rate HOLD until clearer revenue or trial-readout catalysts appear.

HK Stocks

Volume spike 2496.HK Wuhan YZY Biopharma HKSE intraday 29 Jan 2026: Watch liquidity

ByDanny Kontos January 29, 2026January 29, 2026

A sudden volume spike pushed 2496.HK stock to HKD 7.87 intraday on 29 Jan 2026, with 39,400.00 shares traded versus an average of 206.00. The move lifted the day range to a high of HKD 8.35 and flagged a relVolume of 191.26, suggesting an outsized interest in Wuhan YZY Biopharma on the HKSE. There is no scheduled earnings announcement today, so the volume surge likely reflects trade flows or positioning ahead of catalysts. We examine price action, technical risk, valuation, and Meyka AI model projections to frame near-term trade ideas for intraday volume traders.